Korean J Urol.  2014 Jun;55(6):367-379. 10.4111/kju.2014.55.6.367.

The Dark Side of 5alpha-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression

• Traish AM
• Mulgaonkar A
• Giordano N

• KMID: 1885614
• DOI: http://doi.org/10.4111/kju.2014.55.6.367

Abstract

With aging, abnormal benign growth of the prostate results in benign prostate hyperplasia (BPH) with concomitant lower urinary tract symptoms (LUTS). Because the prostate is an androgen target tissue, and transforms testosterone into 5alpha-dihydrotestosterone (5alpha-DHT), a potent androgen, via 5alpha-reductase (5alpha-R) activity, inhibiting this key metabolic reaction was identified as a target for drug development to treat symptoms of BPH. Two drugs, namely finasteride and dutasteride were developed as specific 5alpha-reductase inhibitors (5alpha-RIs) and were approved by the U.S. Food and Drug Administration for the treatment of BPH symptoms. These agents have proven useful in the reducing urinary retention and minimizing surgical intervention in patients with BPH symptoms and considerable literature exists describing the benefits of these agents. In this review we highlight the adverse side effects of 5alpha-RIs on sexual function, high grade prostate cancer incidence, central nervous system function and on depression. 5alpha-Rs isoforms (types 1-3) are widely distributed in many tissues including the central nervous system and inhibition of these enzymes results in blockade of synthesis of several key hormones and neuro-active steroids leading to a host of adverse effects, including loss of or reduced libido, erectile dysfunction, orgasmic dysfunction, increased high Gleason grade prostate cancer, observed heart failure and cardiovascular events in clinical trials, and depression. Considerable evidence exists from preclinical and clinical studies, which point to significant and serious adverse effects of 5alpha-RIs, finasteride and dutasteride, on sexual health, vascular health, psychological health and the overall quality of life. Physicians need to be aware of such potential adverse effects and communicate such information to their patients prior to commencing 5alpha-RIs therapy.

Keyword

5alpha-Reductase inhibitors; Depression; Physiological sexual dysfunction; Prostate neoplasms

MeSH Terms

Aging
Central Nervous System
Depression*
Erectile Dysfunction
Finasteride
Heart Failure
Humans
Hyperplasia
Incidence
Libido
Lower Urinary Tract Symptoms
Male
Orgasm
Prostate
Prostatic Neoplasms*
Protein Isoforms
Quality of Life
Reproductive Health
Sexual Dysfunction, Physiological
Steroids
Testosterone
United States Food and Drug Administration
Urinary Retention
Finasteride
Protein Isoforms
Steroids
Testosterone

Figure

• 

  FIG. 1 Transformation of androgens, progestins and glucocorticoids into 5α-dihydroderivatives by 5α-reductases and tetrahydro-metabolites (neurosteroids) by 3α-hydroxysteroid dehydrogenases. The rate limiting step in this pathway is the catalysis by 5α-reductases.

• 

  FIG. 2 Effects of dutasteride on erectile physiology in the animal model. Graphs showing: (A) intracavernosal pressure (ICP)/mean arterial pressure (MAP) and (B) total ICP at 2.5, 5, and 7.5 voltage levels in control, 8-week dutasteride and 6-week dutasteride plus 2-week washout groups. Data are mean±standard error of the mean (n=8-10). **p<0.01 and ***p<0.001 vs. control group (analysis of variance, Bonferroni post hoc). Adapted from Oztekin CV, et al. J Sex Med 2012;9:1773-81, with permission of John Wiley & Sons, Inc. [38].

• 

  FIG. 3 Effects of long-term treatment with finasteride on corpus cavernosum smooth muscle death. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling quantification of apoptotic index of cavernous smooth muscle cells in rats with or without 5α-reductase inhibitor (5α-RI) treatment. (Left) Apoptotic indexes (ratio of apoptotic cells to all cells) of 2 groups were assessed. For each corpus cavernosum sample, 5 randomly obtained fields were selected, and the mean ratio of apoptotic cells to all cells was used to calculate the apoptotic index. Values for 5 samples in each group presented as ratio±standard deviation. **p<0.001 compared with 5α-RI-treatment group (unpaired t-test); (A) control group and (B) 5α-RI-treated group. Black arrows indicate apoptotic cells with dark brown-stained nuclei: (A) control group and (B) 5α-RI-treated group (ApopTag Peroxidase In Situ Apoptosis Detection Kit, Scale bar=100 µm, ×200). Adapted from Zhang MG, et al. Urology 2013;82:743.e9-15, with permission of Elsevier Inc. [40].

• 

  FIG. 4 Relative and absolute risk of prostate cancer according to modified Gleason score (mGS), PCPT and REDUCE trial. 5α-RI, 5α-reductase inhibitors. I bars indicate 95% confidence intervals. Adapted from Theoret MR, et al. N Engl J Med 2011;365:97-9, with permission of Massachusetts Medical Society [15].

• 

  FIG. 5 Effects of finasteride on the number of activated capsase-3 positive cells present in the cerebellar molecular and granular layers. Photomicrographs showing activated caspase-3 immunoreactivity in the granular layer of the cerebellum of a fetus at 24 hours after infusion with vehicle (control, A), finasteride (B), finasteride+alfaxalone (C), and alfaxalone (D). All fetuses were 131±3 days of gestation at the time of autopsy and tissue collection. (A-D: Scale bar, 10 µm). Color was visualized using streptavidin horseradish peroxidase conjugated to diaminobenzidine. Adopted from Yawno T, et al. Neuroscience 2009;163:838-47, with permission of Elsevier Inc. [82].

Reference

1. Traish AM. 5α-reductases in human physiology: an unfolding story. Endocr Pract. 2012; 18:965–975. PMID: 23246684.

2. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011; 8:872–884. PMID: 21176115.

3. Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, Bielas SL, et al. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell. 2010; 142:203–217. PMID: 20637498.

4. Stiles AR, Russell DW. SRD5A3: a surprising role in glycosylation. Cell. 2010; 142:196–198. PMID: 20655462.

5. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009; 55:310–320. PMID: 18838208.

6. Traish AM, Morgentaler A. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer. 2009; 101:1949–1956. PMID: 19888222.

7. Traish AM, Wotiz HH. Prostatic epidermal growth factor receptors and their regulation by androgens. Endocrinology. 1987; 121:1461–1467. PMID: 3498628.

8. Bechis SK, Otsetov AG, Ge R, Olumi AF. Personalized medicine for the management of benign prostatic hyperplasia. J Urol. 2014; 2. 25. [Epub].http://dx.doi.org/10.1016/j.juro.2014.01.114.

9. Erdemir F, Harbin A, Hellstrom WJ. 5-alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med. 2008; 5:2917–2924. PMID: 19090946.

10. Gur S, Kadowitz PJ, Hellstrom WJ. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf. 2013; 12:81–90. PMID: 23173718.

11. Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011; 8:1747–1753. PMID: 21418145.

12. Romer B, Gass P. Finasteride-induced depression: new insights into possible pathomechanisms. J Cosmet Dermatol. 2010; 9:331–332. PMID: 21122055.

13. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010; 362:1192–1202. PMID: 20357281.

14. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349:215–224. PMID: 12824459.

15. Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011; 365:97–99. PMID: 21675880.

16. U.S. Food and Drug Administration. 2010 Meeting Materials, Oncologic Drugs Advisory Committee [Internet]. Silver Spring: U.S. Food and Drug Administration;c2014. cited 2010 Dec 1. Available from: http://www.fda.gov/advisorycommittees/committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm195226.htm.

17. Thompson IM Jr, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013; 369:603–610. PMID: 23944298.

18. Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2012; 9:2927–2932. PMID: 22789024.

19. Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. 2003; 61:579–584. PMID: 12639651.

20. Baldinotti F, Majore S, Fogli A, Marrocco G, Ghirri P, Vuerich M, et al. Molecular characterization of 6 unrelated Italian patients with 5alpha-reductase type 2 deficiency. J Androl. 2008; 29:20–28. PMID: 17609295.

21. MacLaughlin DT, Donahoe PK. Sex determination and differentiation. N Engl J Med. 2004; 350:367–378. PMID: 14736929.

22. Mainwaring WI. The mechanism of action of androgens. Monogr Endocrinol. 1977; 10:1–178. PMID: 325393.

23. Bradshaw WG, Baum MJ, Awh CC. Attenuation by a 5 alpha-reductase inhibitor of the activational effect of testosterone propionate on penile erections in castrated male rats. Endocrinology. 1981; 109:1047–1051. PMID: 7285860.

24. Gray GD, Smith ER, Davidson JM. Hormonal regulation of penile erection in castrated male rats. Physiol Behav. 1980; 24:463–468. PMID: 7375566.

25. Hart BL. Effects of testosterone propionate and dihydrotestosterone on penile morphology and sexual reflexes of spinal male rats. Horm Behav. 1973; 4:239–246. PMID: 4785734.

26. Hart BL. Activation of sexual reflexes of male rats by dihydrotestosterone but not estrogen. Physiol Behav. 1979; 23:107–109. PMID: 515197.

27. Mantzoros CS, Georgiadis EI, Trichopoulos D. Contribution of dihydrotestosterone to male sexual behaviour. BMJ. 1995; 310:1289–1291. PMID: 7773040.

28. Saksena SK, Lau IF, Chang MC. The inhibition of the conversion of testosterone into 5alpha-dihydrotestosterone in the reproductive organs of the male rat. Steroids. 1976; 27:751–757. PMID: 941190.

29. Baum MJ. A comparison of the effects of methyltrienolone (R1881) and 5 alpha-dihydrotestosterone on sexual behavior of castrated male rats. Horm Behav. 1979; 13:165–174. PMID: 317878.

30. Lugg JA, Rajfer J, Gonzalez-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology. 1995; 136:1495–1501. PMID: 7534702.

31. Penson DF, Ng C, Rajfer J, Gonzalez-Cadavid NF. Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology. 1997; 138:3925–3932. PMID: 9275083.

32. Garban H, Marquez D, Cai L, Rajfer J, Gonzalez-Cadavid NF. Restoration of normal adult penile erectile response in aged rats by long-term treatment with androgens. Biol Reprod. 1995; 53:1365–1372. PMID: 8562693.

33. Park KH, Kim SW, Kim KD, Paick JS. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int. 1999; 83:327–333. PMID: 10233504.

34. Bialy M, Sachs BD. Androgen implants in medial amygdala briefly maintain noncontact erection in castrated male rats. Horm Behav. 2002; 42:345–355. PMID: 12460594.

35. Manzo J, Cruz MR, Hernandez ME, Pacheco P, Sachs BD. Regulation of noncontact erection in rats by gonadal steroids. Horm Behav. 1999; 35:264–270. PMID: 10373338.

36. Sachs BD. Placing erection in context: the reflexogenic-psychogenic dichotomy reconsidered. Neurosci Biobehav Rev. 1995; 19:211–224. PMID: 7630577.

37. Seo SI, Kim SW, Paick JS. The effects of androgen on penile reflex, erectile response to electrical stimulation and penile NOS activity in the rat. Asian J Androl. 1999; 1:169–174. PMID: 11225889.

38. Oztekin CV, Gur S, Abdulkadir NA, Lokman U, Akdemir AO, Cetinkaya M, et al. Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy. J Sex Med. 2012; 9:1773–1781. PMID: 22568670.

39. Pinsky MR, Gur S, Tracey AJ, Harbin A, Hellstrom WJ. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med. 2011; 8:3066–3074. PMID: 21834872.

40. Zhang MG, Wang XJ, Shen ZJ, Gao PJ. Long-term oral administration of 5α-reductase inhibitor attenuates erectile function by inhibiting autophagy and promoting apoptosis of smooth muscle cells in corpus cavernosum of aged rats. Urology. 2013; 82:743.e9–743.e15. PMID: 23876578.

41. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology. 1999; 140:1861–1868. PMID: 10098525.

42. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ. 1996; 155:1251–1259. PMID: 8911291.

43. Tenover JL, Pagano GA, Morton AS, Liss CL, Byrnes CA. Primary Care Investigator Study Group. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Clin Ther. 1997; 19:243–258. PMID: 9152564.

44. Hudson PB, Boake R, Trachtenberg J, Romas NA, Rosenblatt S, Narayan P, et al. The North American Finasteride Study Group. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. Urology. 1999; 53:690–695. PMID: 10197842.

45. Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1999; 54:670–678. PMID: 10510926.

46. Wilton L, Pearce G, Edet E, Freemantle S, Stephens MD, Mann RD. The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. Br J Urol. 1996; 78:379–384. PMID: 8881946.

47. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003; 170(2 Pt 1):530–547. PMID: 12853821.

48. Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol. 2002; 2:14. PMID: 12477383.

49. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Morrill B, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008; 179:616–621. PMID: 18082216.

50. Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A, et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials. 2007; 28:770–779. PMID: 17761460.

51. Desgrandchamps F, Droupy S, Irani J, Saussine C, Comenducci A. Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice. BJU Int. 2006; 98:83–88. PMID: 16831149.

52. Canguven O, Burnett AL. The effect of 5 alpha-reductase inhibitors on erectile function. J Androl. 2008; 29:514–523. PMID: 18421068.

53. Kaplan SA, Chung DE, Lee RK, Scofield S, Te AE. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Int J Clin Pract. 2012; 66:1052–1055. PMID: 23067029.

54. Chi BH, Kim SC. Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results. Korean J Urol. 2011; 52:632–636. PMID: 22025960.

55. Fwu CW, Eggers PW, Kirkali Z, McVary KT, Burrows PK, Kusek JW. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. J Urol. 2013; 12. 14. [Epub]. http://dx.doi.org/10.1016/j.juro.2013.12.014.

56. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002; 167(2 Pt 2):948–951. PMID: 11905923.

57. Olsson M, Ekstrom L, Guillemette C, Belanger A, Rane A, Gustafsson O. Correlation between circulatory, local prostatic, and intra-prostatic androgen levels. Prostate. 2011; 71:909–914. PMID: 21541968.

58. Morgentaler A. Goodbye androgen hypothesis, hello saturation model. Eur Urol. 2012; 62:765–767. PMID: 22728116.

59. Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol. 2012; 62:757–764. PMID: 22658758.

60. Crawford ED, Fair WR, Kelloff GJ, Lieber MM, Miller GJ, Scardíno PT, et al. Chemoprevention of prostate cancer: guidelines for possible intervention strategies. J Cell Biochem Suppl. 1992; 16H:140–145. PMID: 1337764.

61. Justman S. What's wrong with chemoprevention of prostate cancer? Am J Bioeth. 2011; 11:21–25. PMID: 22146025.

62. Walsh PC. Three considerations before advising 5-alpha-reductase inhibitors for chemoprevention. J Clin Oncol. 2009; 27:e22. author reply e23. PMID: 19487370.

63. Walsh PC. Chemoprevention of prostate cancer. N Engl J Med. 2010; 362:1237–1238. PMID: 20357287.

64. Ehdaie B, Touijer KA. 5-alpha Reductase inhibitors in prostate cancer: from clinical trials to clinical practice. Eur Urol. 2013; 63:788–789. PMID: 23305882.

65. Hoffman RM, Roberts RG, Barry MJ. Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory? J Gen Intern Med. 2011; 26:798–801. PMID: 21222171.

66. Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003; 44:82–88. PMID: 12814679.

67. Roehrborn CG, Andriole GL, Wilson TH, Castro R, Rittmaster RS. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Eur Urol. 2011; 59:244–249. PMID: 21093145.

68. Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S A. 1996; 93:11802–11807. PMID: 8876218.

69. Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014; 65:115–123. PMID: 24011426.

70. Hsieh JT, Chen SC, Yu HJ, Chang HC. Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer. Prostate. 2011; 71:1115–1121. PMID: 21557276.

71. Yun DK, Lee J, Keum YS. Finasteride increases the expression of hemoxygenase-1 (HO-1) and NF-E2-related factor-2 (Nrf2) proteins in PC-3 cells: implication of finasteride-mediated high-grade prostate tumor occurrence. Biomol Ther (Seoul). 2013; 21:49–53. PMID: 24009858.

72. Mensah-Nyagan AG, Do-Rego JL, Beaujean D, Luu-The V, Pelletier G, Vaudry H. Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol Rev. 1999; 51:63–81. PMID: 10049998.

73. Akk G, Covey DF, Evers AS, Steinbach JH, Zorumski CF, Mennerick S. Mechanisms of neurosteroid interactions with GABA(A) receptors. Pharmacol Ther. 2007; 116:35–57. PMID: 17524487.

74. Reddy DS. Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy. Front Endocrinol (Lausanne). 2011; 2:38. PMID: 22654805.

75. Melcangi RC, Panzica GC. Allopregnanolone: state of the art. Prog Neurobiol. 2014; 113:1–5. PMID: 24121112.

76. Melcangi RC, Caruso D, Abbiati F, Giatti S, Calabrese D, Piazza F, et al. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. J Sex Med. 2013; 10:2598–2603. PMID: 23890183.

77. He J, Evans CO, Hoffman SW, Oyesiku NM, Stein DG. Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp Neurol. 2004; 189:404–412. PMID: 15380490.

78. VanLandingham JW, Cutler SM, Virmani S, Hoffman SW, Covey DF, Krishnan K, et al. The enantiomer of progesterone acts as a molecular neuroprotectant after traumatic brain injury. Neuropharmacology. 2006; 51:1078–1085. PMID: 16926035.

79. Ishrat T, Sayeed I, Atif F, Hua F, Stein DG. Progesterone and allopregnanolone attenuate blood-brain barrier dysfunction following permanent focal ischemia by regulating the expression of matrix metalloproteinases. Exp Neurol. 2010; 226:183–190. PMID: 20816826.

80. Moralí G, Montes P, González-Burgos I, Velázquez-Zamora DA, Cervantes M. Cytoarchitectural characteristics of hippocampal CA1 pyramidal neurons of rats, four months after global cerebral ischemia and progesterone treatment. Restor Neurol Neurosci. 2012; 30:1–8. PMID: 22377905.

81. Sayeed I, Guo Q, Hoffman SW, Stein DG. Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. Ann Emerg Med. 2006; 47:381–389. PMID: 16546625.

82. Yawno T, Yan EB, Walker DW, Hirst JJ. Inhibition of neurosteroid synthesis increases asphyxia-induced brain injury in the late gestation fetal sheep. Neuroscience. 2007; 146:1726–1733. PMID: 17449186.

83. Ishihara Y, Kawami T, Ishida A, Yamazaki T. Allopregnanolone-mediated protective effects of progesterone on tributyltin-induced neuronal injury in rat hippocampal slices. J Steroid Biochem Mol Biol. 2013; 135:1–6. PMID: 23280249.

84. Romer B, Pfeiffer N, Lewicka S, Ben-Abdallah N, Vogt MA, Deuschle M, et al. Finasteride treatment inhibits adult hippocampal neurogenesis in male mice. Pharmacopsychiatry. 2010; 43:174–178. PMID: 20486040.

85. Mellon SH. Neurosteroid regulation of central nervous system development. Pharmacol Ther. 2007; 116:107–124. PMID: 17651807.

86. Naylor JC, Kilts JD, Hulette CM, Steffens DC, Blazer DG, Ervin JF, et al. Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects. Biochim Biophys Acta. 2010; 1801:951–959. PMID: 20488256.

87. Wong AC, Mak ST. Finasteride-associated cataract and intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2011; 37:1351–1354. PMID: 21555201.

88. Singh S, Hota D, Prakash A, Khanduja KL, Arora SK, Chakrabarti A. Allopregnanolone, the active metabolite of progesterone protects against neuronal damage in picrotoxin-induced seizure model in mice. Pharmacol Biochem Behav. 2010; 94:416–422. PMID: 19840816.

89. Kokate TG, Banks MK, Magee T, Yamaguchi S, Rogawski MA. Finasteride, a 5alpha-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J Pharmacol Exp Ther. 1999; 288:679–684. PMID: 9918575.

90. Lonsdale D, Burnham WM. The anticonvulsant effects of progesterone and 5alpha-dihydroprogesterone on amygdala-kindled seizures in rats. Epilepsia. 2003; 44:1494–1499. PMID: 14636318.

91. Reddy DS, Castaneda DC, O'Malley BW, Rogawski MA. Anticonvulsant activity of progesterone and neurosteroids in progesterone receptor knockout mice. J Pharmacol Exp Ther. 2004; 310:230–239. PMID: 14982969.

92. Kenny B, Ballard S, Blagg J, Fox D. Pharmacological options in the treatment of benign prostatic hyperplasia. J Med Chem. 1997; 40:1293–1315. PMID: 9135028.

93. Khisti RT, Chopde CT, Jain SP. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav. 2000; 67:137–143. PMID: 11113493.

94. Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. J Neuroendocrinol. 1995; 7:171–177. PMID: 7606242.

95. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci U S A. 1998; 95:3239–3244. PMID: 9501247.

96. Le Melledo JM, Baker G. Role of progesterone and other neuroactive steroids in anxiety disorders. Expert Rev Neurother. 2004; 4:851–860. PMID: 15853511.

97. Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012; 73:1220–1223. PMID: 22939118.

98. Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A. Finasteride induced depression: a prospective study. BMC Clin Pharmacol. 2006; 6:7. PMID: 17026771.

99. Gubelin Harcha W, Barboza Martinez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014; 70:489–498.e3. PMID: 24411083.

100. Irwig MS. Persistent sexual and nonsexual adverse effects of finasteride in younger men. Sex Med Rev. 2014; 2:24–35.